Background
dengue
DENGUE, VIRUS, YELLOW FEVER
I have read the journal’s policy and the authors of this manuscript have the following competing interests: VT, IE, MR, MB, IL and DW are full-time employees of Takeda. AB was employee of Takeda at the time of the study (current affiliation of AB: HilleVax GmbH, Zurich, Switzerland). BE, JEE, and MT received funding from Takeda Vaccines to perform the trial.Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individuals. This phase 3 study assessed the immunogenicity and safety of concomitant and sequential administration of YF (YF-17D) and tetravalent dengue (TAK-003) vaccines in healthy adults aged 18–60 years living in areas of the US non-endemic for either virus.